{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:34:54Z","timestamp":1700620494434},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T00:00:00Z","timestamp":1270771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2482-10-15","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T14:14:42Z","timestamp":1270822482000},"source":"Crossref","is-referenced-by-count":8,"title":["A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT"],"prefix":"10.1186","volume":"10","author":[{"given":"Armin D","family":"Goralczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schnitzbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung Y","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Ramadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiman","family":"Obed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,9]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1399-0012.2003.00132.x","volume":"18","author":"AS Paramesh","year":"2004","unstructured":"Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS, Akalin E: Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant. 2004, 18: 94-99. 10.1046\/j.1399-0012.2003.00132.x.","journal-title":"Clin Transplant"},{"issue":"10","key":"162_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa021744","volume":"349","author":"AO Ojo","year":"2003","unstructured":"Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003, 349 (10): 931-940. 10.1056\/NEJMoa021744.","journal-title":"N Engl J Med"},{"key":"162_CR3","unstructured":"2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006. 2007, Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation"},{"issue":"6","key":"162_CR4","first-page":"356","volume":"49","author":"MJ Mihatsch","year":"1998","unstructured":"Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B: The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol. 1998, 49 (6): 356-363.","journal-title":"Clin Nephrol"},{"issue":"13-14","key":"162_CR5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.intimp.2006.09.022","volume":"6","author":"I Bilbao","year":"2006","unstructured":"Bilbao I, Castells L, Rojas L, Cancino J, Dopazo C, Castro E, Pou L, Andino R, Margarit C: Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol. 2006, 6 (13-14): 1977-1983. 10.1016\/j.intimp.2006.09.022.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"162_CR6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","volume":"72","author":"TA Gonwa","year":"2001","unstructured":"Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB: End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001, 72 (12): 1934-1939. 10.1097\/00007890-200112270-00012.","journal-title":"Transplantation"},{"issue":"2","key":"162_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/tr.2000.5377","volume":"14","author":"GM Danovitch","year":"2000","unstructured":"Danovitch GM: Immunosuppressant-induced metabolic toxicities. Transplant Rev. 2000, 14 (2): 65-81. 10.1053\/tr.2000.5377.","journal-title":"Transplant Rev"},{"issue":"6","key":"162_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2165\/00002018-199921060-00004","volume":"21","author":"AJ Olyaei","year":"1999","unstructured":"Olyaei AJ, de Mattos AM, Bennett WM: Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf. 1999, 21 (6): 471-488. 10.2165\/00002018-199921060-00004.","journal-title":"Drug Saf"},{"issue":"9256","key":"162_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0140-6736(00)04055-1","volume":"357","author":"HJ Schlitt","year":"2001","unstructured":"Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001, 357 (9256): 587-591. 10.1016\/S0140-6736(00)04055-1.","journal-title":"Lancet"},{"issue":"9","key":"162_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.transproceed.2004.10.008","volume":"36","author":"S Beckebaum","year":"2004","unstructured":"Beckebaum S, Cicinnati VR, Klein CG, Brokalaki E, Yu Z, Malago M, Frilling A, Gerken G, Broelsch CE: Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc. 2004, 36 (9): 2671-2674. 10.1016\/j.transproceed.2004.10.008.","journal-title":"Transplant Proc"},{"key":"162_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.TP.0000165118.00988.D7","volume":"80","author":"DJ Reich","year":"2005","unstructured":"Reich DJ, Clavien PA, Hodge EE: Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005, 80: 18-25. 10.1097\/01.TP.0000165118.00988.D7.","journal-title":"Transplantation"},{"issue":"12","key":"162_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/lt.20903","volume":"12","author":"GP Pageaux","year":"2006","unstructured":"Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, Bernard PH, Barbotte E, Vercambre L, Bismuth M, Puche P, Navarro F, Larrey D: Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 2006, 12 (12): 1755-1760. 10.1002\/lt.20903.","journal-title":"Liver Transpl"},{"issue":"3","key":"162_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/01.ASN.0000113248.59077.76","volume":"15","author":"H Kreis","year":"2004","unstructured":"Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004, 15 (3): 809-817. 10.1097\/01.ASN.0000113248.59077.76.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"162_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","volume":"9","author":"JM Neuberger","year":"2009","unstructured":"Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD: Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009, 9 (2): 327-336. 10.1111\/j.1600-6143.2008.02493.x.","journal-title":"Am J Transplant"},{"issue":"12","key":"162_CR15","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1097\/01.TP.0000065740.69296.DA","volume":"75","author":"TG Heffron","year":"2003","unstructured":"Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R: Pediatric liver transplantation with daclizumab induction. Transplantation. 2003, 75 (12): 2040-2043. 10.1097\/01.TP.0000065740.69296.DA.","journal-title":"Transplantation"},{"issue":"9","key":"162_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/lt.20490","volume":"11","author":"EM Yoshida","year":"2005","unstructured":"Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JST: Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005, 11 (9): 1064-1072. 10.1002\/lt.20490.","journal-title":"Liver Transpl"},{"issue":"10","key":"162_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/lt.20520","volume":"11","author":"CC Lin","year":"2005","unstructured":"Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL: The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl. 2005, 11 (10): 1258-1264. 10.1002\/lt.20520.","journal-title":"Liver Transpl"},{"issue":"2","key":"162_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/jlts.2002.30302","volume":"8","author":"P Neuhaus","year":"2002","unstructured":"Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B: Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002, 8 (2): 132-142. 10.1053\/jlts.2002.30302.","journal-title":"Liver Transpl"},{"issue":"2","key":"162_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/jlts.2002.30882","volume":"8","author":"Y Calmus","year":"2002","unstructured":"Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D: Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002, 8 (2): 123-131. 10.1053\/jlts.2002.30882.","journal-title":"Liver Transpl"},{"key":"162_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00007890-200101150-00028","volume":"71","author":"GA Levy","year":"2001","unstructured":"Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM: Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl] rapamycin in de novo liver transplant recipients. Transplantation. 2001, 71: 160-163. 10.1097\/00007890-200101150-00028.","journal-title":"Transplantation"},{"issue":"11","key":"162_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/lt.20707","volume":"12","author":"G Levy","year":"2006","unstructured":"Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L: Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006, 12 (11): 1640-1648. 10.1002\/lt.20707.","journal-title":"Liver Transpl"},{"issue":"2","key":"162_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","volume":"28","author":"T van Gelder","year":"2006","unstructured":"van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD: Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006, 28 (2): 145-154. 10.1097\/01.ftd.0000199358.80013.bd.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"162_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/lt.20490","volume":"11","author":"EM Yoshida","year":"2005","unstructured":"Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JST: Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005, 11 (9): 1064-1072. 10.1002\/lt.20490.","journal-title":"Liver Transpl"},{"issue":"6","key":"162_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/jlts.2000.19023","volume":"6","author":"GJ Chang","year":"2000","unstructured":"Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R: Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 2000, 6 (6): 734-740. 10.1053\/jlts.2000.19023.","journal-title":"Liver Transpl"},{"key":"162_CR25","first-page":"CD005161","volume":"4","author":"EM Haddad","year":"2006","unstructured":"Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL: Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006, 4: CD005161-","journal-title":"Cochrane Database Syst Rev"},{"key":"162_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989, 10: 1-10. 10.1016\/0197-2456(89)90015-9.","journal-title":"Control Clin Trials"},{"key":"162_CR27","volume-title":"Sample Size Calculations in Clinical Research","author":"SC Chow","year":"2008","unstructured":"Chow SC, Shao J, Wang H: Sample Size Calculations in Clinical Research. 2008, Chapman and Hall\/CRC"},{"key":"162_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2307\/2685469","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull B: Approximate is Better than \"Exact\" for Interval Estimation of Binomial Proportions. American Statistician. 1998, 52: 119-26. 10.2307\/2685469.","journal-title":"American Statistician"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2482-10-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2482-10-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2482-10-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T22:55:45Z","timestamp":1468104945000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/1471-2482-10-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1186\/1471-2482-10-15","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,9]]},"article-number":"15"}}